Results 1 to 10 of about 9,005,815 (383)

Critical molecular pathways in CLL therapy [PDF]

open access: yesMolecular Medicine, 2018
Chronic lymphocytic leukemia (CLL), the most frequent type of leukemia in western countries, is characterized by the progressive accumulation in blood, bone marrow and lymphoid tissues of monoclonal B lymphocytes with a characteristic immunophenotype ...
Gerardo Ferrer, Emili Montserrat
doaj   +5 more sources

Type 2 Diabetes, Obesity, and Cancer Share Some Common and Critical Pathways. [PDF]

open access: yesFront Oncol, 2020
Diabetes and cancer are among the most frequent and complex diseases. Epidemiological evidence showed that the patients suffering from diabetes are significantly at higher risk for a number of cancer types. There are a number of evidence that support the
Rahman I, Athar MT, Islam M.
europepmc   +2 more sources

Critical Pathways [PDF]

open access: bronzeCirculation, 2000
Critical pathways, also known as critical paths, clinical pathways, or care paths, are management plans that display goals for patients and provide the sequence and timing of actions necessary to achieve these goals with optimal efficiency.1 As competition in the healthcare industry has increased, managers have embraced critical pathways as a method to
Judith S. Hochman   +4 more
openaire   +3 more sources

Identification of cell proliferation, immune response and cell migration as critical pathways in a prognostic signature for HER2+:ERα- breast cancer. [PDF]

open access: yesPLoS One, 2017
Background Multi-gene prognostic signatures derived from primary tumor biopsies can guide clinicians in designing an appropriate course of treatment.
Liu JC   +4 more
europepmc   +2 more sources

Progenitor B-1 B-cell acute lymphoblastic leukemia is associated with collaborative mutations in 3 critical pathways. [PDF]

open access: yesBlood Adv, 2017
B-1 and B-2 lymphocytes are derived from distinct developmental pathways and represent layered arms of the innate and adaptive immune systems, respectively.
Gough SM   +14 more
europepmc   +2 more sources

Evaluation of a critical pathway for stroke [PDF]

open access: hybridJournal of Osteopathic Medicine, 1997
Abstract The diagnosis of stroke, which is diagnosis-related group (DRG) 014, is the fourth most frequent discharge DRG at Macomb Hospital Center, Warren, Michigan. The length of stay for stroke was 7.52 days before intervention. Quality improvement techniques identified areas of delay that presented opportunities for improvement.
Gary Ross   +2 more
openaire   +4 more sources

A study exploring critical pathways in clear cell renal cell carcinoma. [PDF]

open access: yesExp Ther Med, 2014
Renal cell carcinoma (RCC) is the most lethal type of cancer in the urinary system and often presents as a metastatic disease. Furthermore, there are no effective treatments for the disease.
Zeng Z, Que T, Zhang J, Hu Y.
europepmc   +2 more sources

Critical signaling pathways governing hepatocellular carcinoma behavior; small molecule-based approaches

open access: yesCancer Cell International, 2021
Hepatocellular carcinoma (HCC) is the second leading cause of death due to cancer. Although there are different treatment options, these strategies are not efficient in terms of restricting the tumor cell’s proliferation and metastasis.
Zahra Farzaneh   +3 more
doaj   +2 more sources

Decreasing medical complications for total knee arthroplasty: Effect of Critical Pathways on Outcomes [PDF]

open access: yesBMC Musculoskeletal Disorders, 2010
BackgroundStudies on critical pathway use have demonstrated decreased length of stay and cost without compromise in quality of care. However, pathway effectiveness is difficult to determine given methodological flaws, such as small or single center ...
Ms Elaine Husni   +5 more
semanticscholar   +5 more sources

SMAD4 loss enables EGF, TGFβ1 and S100A8/A9 induced activation of critical pathways to invasion in human pancreatic adenocarcinoma cells. [PDF]

open access: yesOncotarget, 2016
Epidermal Growth Factor (EGF) receptor overexpression, KRAS, TP53, CDKN2A and SMAD4 mutations characterize pancreatic ductal adenocarcinoma. This mutational landscape might influence cancer cells response to EGF, Transforming Growth Factor \u3b21 (TGF ...
Moz S   +14 more
europepmc   +3 more sources

Home - About - Disclaimer - Privacy